KRAS and non-small cell lung carcinoma: Another phase II clinical trial comparing the MEK inhibitor, trametinib, to docetaxel, a microtubule depolymerization inhibitor in KRAS-mutant NSCLC patients, revealed no significant difference in survival outcomes [79].